Armin Atzinger
Impact in
-
- Peptidase Inhibition and Analysis
- CAR-T cell therapy research
-
- Protease and Inhibitor Mechanisms
Papers in
- Oncology 11
- Peptidase Inhibition and Analysis 9
-
- Radiopharmaceutical Chemistry and Applications 4
- Co-authors
- Torsten Kuwert (20 shared papers)Christian Schmidkonz (16 shared papers)Georg Schett (11 shared papers)Arnd Kleyer (6 shared papers)Michael Uder (4 shared papers)M. Cordes (5 shared papers)Andreas Ramming (7 shared papers)Frank W. Roemer (2 shared papers)
In The Last Decade
Armin Atzinger
22 papers receiving 220 citations
Hit Papers
Peers
Comparison fields: 5 of 33
- Oncology 122
- Cancer Research 41
- Radiology, Nuclear Medicine and Imaging 56
- Immunology 45
- Rheumatology 31
Countries citing papers authored by Armin Atzinger
This map shows the geographic impact of Armin Atzinger's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Armin Atzinger with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Armin Atzinger more than expected).
Fields of papers citing papers by Armin Atzinger
This network shows the impact of papers produced by Armin Atzinger. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Armin Atzinger. The network helps show where Armin Atzinger may publish in the future.
Co-authors
The 25 scholars most cited alongside Armin Atzinger, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 26 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | 2023 | 55 | |
| 2 | 2022 | 35 | |
| 3 | 2022 | 22 | |
| 4 | 2023 | 17 | |
| 5 | BCMA CAR T cells in a patient with relapsing idiopathic inflammatory myositis after initial and repeat therapy with CD19 CAR T cells Hit paper breakdown → | 2025 | 15 |
| 6 | 2019 | 14 | |
| 7 | 2020 | 10 | |
| 8 | 2024 | 9 | |
| 9 | 2024 | 7 | |
| 10 | 2019 | 7 | |
| 11 | 2022 | 6 | |
| 12 | 2023 | 5 | |
| 13 | 2023 | 4 | |
| 14 | 2024 | 3 | |
| 15 | 2023 | 3 | |
| 16 | 2024 | 2 | |
| 17 | 2023 | 2 | |
| 18 | 2024 | 1 | |
| 19 | 2024 | 1 | |
| 20 | 2025 | 1 |
About Armin Atzinger
Armin Atzinger is a scholar working on Oncology, Radiology, Nuclear Medicine and Imaging, Cancer Research, Pulmonary and Respiratory Medicine and Rheumatology, having authored 26 papers that have together received 221 indexed citations. Recurring topics across this work include Peptidase Inhibition and Analysis (9 papers), Protease and Inhibitor Mechanisms (6 papers), Rheumatoid Arthritis Research and Therapies (5 papers), Radiopharmaceutical Chemistry and Applications (4 papers), Immunodeficiency and Autoimmune Disorders (3 papers), Inflammatory Myopathies and Dermatomyositis (3 papers), Sarcoidosis and Beryllium Toxicity Research (3 papers) and Spondyloarthritis Studies and Treatments (3 papers). The work is most often cited by research in Oncology (122 citations), Cancer Research (41 citations), Radiology, Nuclear Medicine and Imaging (56 citations), Immunology (45 citations) and Rheumatology (31 citations). Armin Atzinger has collaborated with scholars based in Germany, Portugal and Ireland. Frequent co-authors include Torsten Kuwert, Christian Schmidkonz, Georg Schett, Arnd Kleyer, Michael Uder, M. Cordes, Andreas Ramming, Frank W. Roemer, Jule Taubmann and Sascha Kretschmann. Their work appears in journals such as Annals of the Rheumatic Diseases, RMD Open, Lara D. Veeken, Journal of Nuclear Medicine and European Journal of Nuclear Medicine and Molecular Imaging.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.